Revance Therapeutics
Newark, NJ
Revance Therapeutics, Inc. produces biopharmaceutical products. The Company develops drug delivery and treatments for dermatology and aesthetic medicine. Revance Therapeutics serves patients and doctors throughout the United States.
revance.comCompany Details
Founded
- 2002
Employees
- Between 500 - 1,000 employees
Raised
- $1,679,526,016
Headquarters Location
- Newark, NJ
Public
- Yes
Acquired
- Yes
CEO
Mark Foley
Company Collections
These are collections Revance Therapeutics is a part of. Click on the collection name to view similar companies.
Revance Therapeutics' Industries
Revance Therapeutics' Tech Stack
Revance Therapeutics Headquarters Location
Total Amount Raised: $1,679,526,016
Revance Therapeutics Funding Rounds
Post Ipo Equity
$100,000,000
Post Ipo Equity
$100,000,000
Post Ipo Equity
$200,000,000
Post Ipo Equity
$200,000,000
Post Ipo Debt
$300,000,000
Post Ipo Debt
$300,000,000
Post Ipo Debt Investors
Athyrium Capital ManagementPost Ipo Debt
$250,000,000
Post Ipo Debt
$250,000,000
Post Ipo Equity
$110,500,000
Post Ipo Equity
$110,500,000
Post Ipo Equity
$115,000,000
Post Ipo Equity
$115,000,000
Post Ipo Equity
$167,100,000
Post Ipo Equity
$167,100,000
Post Ipo Equity Investors
RamiusPost Ipo Equity
$126,000,000
Post Ipo Equity
$126,000,000
Post Ipo Equity
$131,300,000
Post Ipo Equity
$131,300,000
IPO
Unknown
IPO
Unknown
Series Unknown
$10,000,000
Series Unknown
$10,000,000
Series E
$33,000,000
Series E
$33,000,000
Series E Investors
Essex WoodlandsNovaQuest Capital ManagementDelphi VenturesSeries D
$45,000,000
Series D
$45,000,000
Series D Investors
Essex WoodlandsNovaQuest Capital ManagementTechnology PartnersPalo Alto InvestorsCNF InvestmentsShepherd VenturesVivo CapitalPac-LinkEssex CapitalSeries D
$25,620,000
Series D
$25,620,000
Series D Investors
Essex WoodlandsTechnology PartnersShepherd VenturesPalo Alto InvestorsEDBIPac-LinkVivo CapitalBio*One CapitalDebt Financing
$8,000,000
Debt Financing
$8,000,000
Debt Financing Investors
Leader VenturesHorizon Technology FinanceSeries C
$43,200,000
Series C
$43,200,000
Series C Investors
Medicis PharmaceuticalEssex WoodlandsTechnology PartnersShepherd VenturesPalo Alto InvestorsVivo CapitalSeries B
$13,000,000
Series B
$13,000,000
Series B Investors
Essex WoodlandsTechnology PartnersVivo CapitalSeries A
$1,806,000
Series A
$1,806,000
Revance Therapeutics Reviews
0 out of 5 stars
Based on 0 reviews
Review data
Share your thoughts
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Revance Therapeutics.